Spyre Therapeutics (SYRE) Stock: Buy, Sell, or Hold?
SYRE - Spyre Therapeutics, Inc. Common Stock
$90.60
1.89 (2.13%)
▲
5d:
+3.84%
30d:
-12.96%
90d:
+12.17%
BUY
HIGH Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When SYRE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: SYRE shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: SYRE shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: SYRE is currently trading at $90.60, which is considered oversold relative to its 30-day fair value range of $92.08 to $106.98.
Technical Outlook: Technically, SYRE is in a strong uptrend. Immediate support is located at $84.00, while resistance sits at $93.39.
Market Sentiment: SYRE scores 75/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $120.08 (+32.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SYRE is in a strong uptrend. Immediate support is located at $84.00, while resistance sits at $93.39.
Market Sentiment: SYRE scores 75/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $120.08 (+32.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$92.08 -
$106.98
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 32.5% below Wall St target ($120.08)
- BULLISH: Bottoming setup score 75/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$92.08 -
$106.98
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$84.00
Resistance Level
$93.39
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-25.72
Wall Street Target
$120.08
(+32.5%)
Earnings Growth (YoY)
-99.7%
Share & Embed Analysis
Last updated: September 12, 2026 6:42 AM ET
Data refreshes hourly during market hours. Next update: 7:42 AM
Data refreshes hourly during market hours. Next update: 7:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SYRE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Cameron Turtle
SELL
15000 shares
2026-04-01
Scott L Burrows
SELL
7500 shares
2026-04-01
Sheldon Sloan
SELL
7958 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 48 HOLD |
